NPT
REGN icon

Nixon Peabody Trust’s Regeneron Pharmaceuticals REGN Stock Holding History

Nixon Peabody Trust’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-430
Closed -$306K – 158
2024
Q4 		$306K Buy
430
+32
+8% +$26.9K 0.03% 125
2024
Q3 		$418K Sell
398
-32
-7% -$35.6K 0.03% 108
2024
Q2 		$452K Sell
430
-106
-20% -$103K 0.04% 95
2024
Q1 		$516K Buy
+536
New +$510K 0.05% 86

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nixon Peabody Trust's REGN Position: Q1 2025 in Review

Nixon Peabody Trust sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 430 shares — an estimated $306K sold.

Nixon Peabody Trust first reported a position in REGN in Q1 2024 and held it in 4 quarters. The position peaked at $516K in Q1 2024. 1,290 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • Nixon Peabody Trust reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Nixon Peabody Trust sold 430 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $306K.
  • Nixon Peabody Trust first reported a position in Regeneron Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Nixon Peabody Trust's Regeneron Pharmaceuticals position peaked at $516K in Q1 2024.
  • 1,290 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Nixon Peabody Trust's 13F filing for Q1 2025, filed 10 Apr 2025.